NCT02727803 and NCT02727803, both CML clinical trials, similarly demonstrated that infusion of the allogeneic NK cell line NK92 or primary CD56+CD3- NK cells, respectively, significantly reduced BCR-ABL gene expression compared to controls (Table 1). This evidence concerns the gene NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive.